Corvus Pharmaceuticals, Inc. Current Liabilities
Corvus Pharmaceuticals, Inc. (CRVS) had Current Liabilities of $13.67 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $13.67M.
- 2026-03-31: Liabilities, Current $12.11M.
- 2025-12-31: Liabilities, Current $9.38M.
- 2025-09-30: Liabilities, Current $8.07M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $13.67M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $12.11M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $9.38M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $8.07M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $8.51M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $9.28M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $35.40M 10-K · filed 2026-03-12 |
| 2024-09-30 | $46.41M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $13.34M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $6.72M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $6.87M 10-K · filed 2025-03-25 |
| 2023-09-30 | $7.30M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $7.86M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $8.29M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $10.75M 10-K · filed 2024-03-19 |
| 2022-09-30 | $13.98M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $10.16M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $9.27M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $9.69M 10-K · filed 2023-03-28 |
| 2021-09-30 | $11.30M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $12.36M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $13.92M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $12.15M 10-K · filed 2022-03-10 |
| 2020-09-30 | $12.00M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $11.55M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $11.71M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $10.22M 10-K · filed 2021-03-25 |
| 2019-09-30 | $9.52M 10-Q · filed 2019-10-29 |
| 2019-06-30 | $10.70M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $8.63M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $7.03M 10-K · filed 2020-03-09 |
| 2018-09-30 | $7.75M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $9.78M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $10.60M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $8.97M 10-K · filed 2019-03-07 |
| 2017-09-30 | $9.97M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $9.52M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $7.58M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $5.94M 10-K · filed 2018-03-01 |
| 2016-09-30 | $5.60M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $3.61M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $3.38M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $3.07M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |